United States Biotechnology & Medical Research

Roivant Sciences Ltd (ROIV)

Track

Over the last 90 days, Roivant Sciences Ltd. has seen significant insider selling, with a net value of -$45.7 million. Executives accounted for -$42.6 million of this net selling. Notable transactions include multiple large sales by Eric Venker and Matthew Gline, totaling millions of dollars.
Stock chart
Ticker: ROIV Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Venker Eric
President & Immunovant CEO
2 sales — total 200,000 USD
Sale 22 May 2026
Value US$4,611,033.97 | Price 315.26 | Shares 47,089
Proposed sale 22 May 2026
Value US$3,679,275.46 | Price 173.65 | Shares 7,526
Sale 20 Apr 2026
Value US$4,112,034.30 | Price 322.54 | Shares 98,193
Proposed sale 20 Apr 2026
Value US$3,452,418.13 | Price 290.30 | Shares 47,743
Sale 16 Apr 2026
Value US$8,449,809.84 | Price 29.16 | Shares 289,774
Proposed sale 16 Apr 2026
Value US$8,449,876.49 | Price 29.16 | Shares 289,774
Proposed sale 16 Apr 2026
Value US$8,449,876.49 | Price 29.16 | Shares 289,774
Sale 8 Apr 2026
Value US$384,073.06 | Price 28.37 | Shares 13,538
Proposed sale 8 Apr 2026
Value US$384,035.15 | Price 28.37 | Shares 13,538
Sale 26 Mar 2026
Value US$1,921,500.00 | Price 27.45 | Shares 70,000
Proposed sale 26 Mar 2026
Value US$1,921,458.00 | Price 27.45 | Shares 70,000
Sale 17 Mar 2026
Value US$5,648,000.00 | Price 28.24 | Shares 200,000
Proposed sale 17 Mar 2026
Value US$5,648,836.44 | Price 28.24 | Shares 200,000
Sale 16 Mar 2026
Value US$1,200,573.48 | Price 28.68 | Shares 41,861
Proposed sale 16 Mar 2026
Value US$1,200,498.13 | Price 28.68 | Shares 41,861
Sale 23 Feb 2026
Value US$16,159,098.90 | Price 27.51 | Shares 587,390
Sale 20 Feb 2026
Value US$27,492,361.50 | Price 27.15 | Shares 1,012,610
Proposed sale 20 Feb 2026
Value US$44,032,000.00 | Price 27.52 | Shares 1,600,000
Sale 19 Feb 2026
Value US$38,388,000.00 | Price 27.42 | Shares 1,400,000
Proposed sale 19 Feb 2026
Value US$38,472,000.00 | Price 27.48 | Shares 1,400,000
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-22 2026-05-22 S Sale
2.2
Venker Eric

President & Immunovant CEO

Officer
47,089 +9.5%
315.26
US$4,611,034 		47,089 +9.5% 315.26 US$4,611,034
2026-05-22 2026-05-22 PrS Proposed sale
2.2
Venker Eric

Officer

Officer
7,526
173.65
US$3,679,275 		7,526 173.65 US$3,679,275
2026-04-22 2026-04-20 S Sale
2.2
Venker Eric

President & Immunovant CEO

Officer
98,193 +32.7%
322.54
US$4,112,034 		98,193 +32.7% 322.54 US$4,112,034
2026-04-20 2026-04-20 PrS Proposed sale
2.2
Venker Eric

Officer

Officer
200,000
29.59
US$5,917,135 		200,000 29.59 US$5,917,135
2026-04-20 2026-04-16 S Sale
2.3
Gline Matthew

CEO

Executive Director
289,774 -1.7%
29.16
US$8,449,810 		289,774 -1.7% 29.16 US$8,449,810
2026-04-16 2026-04-16 PrS Proposed sale
2.3
Gline Matthew

Officer

Officer
289,774
29.16
US$8,449,876 		289,774 29.16 US$8,449,876
2026-04-16 2026-04-16 PrS Proposed sale
2.3
Gline Matthew

Officer

Officer
289,774
29.16
US$8,449,876 		289,774 29.16 US$8,449,876
2026-04-10 2026-04-08 S Sale
Humes Jennifer

Chief Accounting Officer

Officer
13,538 -13.9%
28.37
US$384,073 		13,538 -13.9% 28.37 US$384,073
2026-04-08 2026-04-08 PrS Proposed sale
JENNIFER HUMES

Officer

Officer
13,538
28.37
US$384,035 		13,538 28.37 US$384,035
2026-03-30 2026-03-26 S Sale
3.6
Fitzgerald Meghan
Non-Executive Director
70,000 -62.0%
27.45
US$1,921,500 		70,000 -62.0% 27.45 US$1,921,500
2026-03-26 2026-03-26 PrS Proposed sale
3.6
MEGHAN FITZGERALD

Director

Non-Executive Director
70,000
27.45
US$1,921,458 		70,000 27.45 US$1,921,458
2026-03-19 2026-03-17 S Sale
2.2
Venker Eric

President & Immunovant CEO

Officer
200,000 -10.8%
28.24
US$5,648,000 		200,000 -10.8% 28.24 US$5,648,000
2026-03-17 2026-03-17 PrS Proposed sale
2.2
Venker Eric

Officer

Officer
200,000
28.24
US$5,648,836 		200,000 28.24 US$5,648,836
2026-03-18 2026-03-16 S Sale
Epperly Melissa B,
Non-Executive Director
41,861 -72.6%
28.68
US$1,200,573 		41,861 -72.6% 28.68 US$1,200,573
2026-03-16 2026-03-16 PrS Proposed sale
MELISSA B EPPERLY

Director

Non-Executive Director
41,861
28.68
US$1,200,498 		41,861 28.68 US$1,200,498
2026-02-23 2026-02-23 S Sale
2.3
Torti Frank

President and Vant Chair

Officer
587,390 -4.1%
27.51
US$16,159,099 		587,390 -4.1% 27.51 US$16,159,099
2026-02-23 2026-02-20 S Sale
2.3
Torti Frank

President and Vant Chair

Officer
1,012,610 -6.9%
27.15
US$27,492,362 		1,012,610 -6.9% 27.15 US$27,492,362
2026-02-20 2026-02-20 PrS Proposed sale
2.3
FRANK TORTI

Officer

Officer
1,600,000
27.52
US$44,032,000 		1,600,000 27.52 US$44,032,000
2026-02-23 2026-02-19 S Sale
2.3
Torti Frank

President and Vant Chair

Officer
1,400,000 -9.2%
27.42
US$38,388,000 		1,400,000 -9.2% 27.42 US$38,388,000
2026-02-19 2026-02-19 PrS Proposed sale
2.3
FRANK TORTI

Officer

Officer
1,400,000
27.48
US$38,472,000 		1,400,000 27.48 US$38,472,000
Explore more

More insider trading research around Roivant Sciences Ltd

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America